Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DMXC $.0086 x $.009 been under solid accumulation the past couple of days. Looks like it's ready to head back over $.01
DMXC looking good here $.0086 x $.009 been under solid accumulation past few days
DMXC $.0086 x $.009 looks like it's about to get jiggy my friend
looks like it's heading back over $.01
the tip was to buy some PNXE lol
PNXE in play
Just got tipped off here...looking good...breakout volume looks like
After yesterday's news everyone seemed to think that FDA approval was a long shot. Now after reading today's news...it appears that optimism is returning here...
tanking now
Notice of Special Meeting of Shareholders
Friday, April 9, 2010
To Cell Therapeutics, Inc. Shareholders:
The Special Meeting of Shareholders (the “Special Meeting”) of Cell Therapeutics, Inc. (the “Company”) will be held at 10:00 a.m. Pacific Daylight Time (PDT), on Friday, April 9, 2010, at 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119, USA, for the following purposes:
(1) to approve an amendment to the Company’s amended and restated articles of incorporation to increase the total number of authorized shares from 810,000,000 to 1,210,000,000 and to increase the total number of authorized shares of common stock from 800,000,000 to 1,200,000,000; and
(2) to approve an amendment to the Company’s 2007 Equity Incentive Plan, as amended (the “2007 Equity Plan”), to increase the number of shares available for issuance under the 2007 Equity Plan by 40,000,000 shares.
All shareholders are invited to attend the Special Meeting. Shareholders of record at the close of business on February 19, 2010, the record date fixed by the Board of Directors of the Company, are entitled to vote at the Special Meeting and all adjournments and postponements thereof. A complete list of shareholders entitled to notice of, and to vote at, the Special Meeting will be open to examination by the shareholders beginning ten (10) days prior to the Special Meeting for any purpose germane to the Special Meeting during normal business hours at the office of the secretary of the Company at 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.
Cell Therapeutics spokesman Dan Eramian said many of the key issues raised by FDA staff were addressed in a company summary prepared for the panel.
In the summary, the company said pixantrone worked better than other drugs with 'manageable toxicities.' Twenty percent of patients treated with pixantrone met the study's main goal of having a major decrease in their disease, compared with about 6 percent with a different medicine.
so the FDA board members can load cheap...lol
here comes the panic
ruh-roh
lets see if it holds here again
Looks like there was strong support @ $.75
Anyone remember DNDN...more specifically what happened to the stock in April of 2009? I believe there was an orchestrated "share raid" that took place...DNDN was trading at a high of $25 that day...somehow a massive panic was triggered sending the stock to a low of $7.50...at any rate, the next day the stock was at a high of $27.50...go figure.
Now, that's not to say that's what will happen with CTIC...it just goes to show how the big boys can play dirty when they want to. This stock is 60% owned by institutions...so believe me...there are big boys here playing games.
CTIC will be a zip code changer upon FDA announcement...the question is will the zip code be in the hamptons or in the hood.
yeah this is insane volume for this stock
DDSS bouncing off the middle bolly now
DDSS - today's FDA approval should make for a nice trading day
NEWS! Achillion Announces Closing of Underwriters' Over-Allotment Option
4:00p ET February 2, 2010 (GlobeNewswire)
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it closed the sale of an additional 1,541,250 shares of its common stock in connection with the exercise of the over-allotment option granted to the underwriters of its recent offering of 10,275,000 shares of common stock. Upon closing of the purchase of the over-allotment shares, a total of 11,816,250 shares of common stock have been sold, resulting in gross proceeds of $24.6 million, before commissions and expenses, and net proceeds before expenses of $22.9 million. Roth Capital Partners acted as sole book-running manager for the offering, and Noble Financial Capital Markets and National Securities acted as co-managers.
The shares of common stock are being offered pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission on October 16, 2009. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering.
Copies of the final prospectus supplement and accompanying base prospectus relating to the offering can be obtained at the SEC's website at http://www.sec.gov. Copies may also be obtained by contacting Roth Capital Partners by e-mail to rothecm@roth.com, by fax to (949) 720-7227, or by mail to 24 Corporate Plaza Drive, Newport Beach, CA, 92660, Attention: Equity Capital Markets.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - hepatitis C, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
ACHN-G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Achillion Pharmaceuticals, Inc.
CONTACT: Achillion Pharmaceuticals, Inc.
Mary Kay Fenton
(203) 624-7000
mfenton@achillion.com
Lippert/Heilshorn & Associates, Inc
Investors:
Anne Marie Fields
(212) 838-3777
afields@lhai.com
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Achillion Announces Closing Of Underwriters' Over-Allotment OptionLast update: 2/2/2010 4:00:17 PM(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)February 02, 2010 16:00 ET (21:00 GMT
ACHN looks like the shorts are covering! Over 25% of the float is short...could trigger a huge short squeeze to send us flying past $3
ACHN looks like the shorts are covering! Over 25% of the float is short...could trigger a huge short squeeze!
ACHN looks like the shorts are covering! Over 25% of the float is short...could trigger a huge short squeeze!
DMXC $.0135 x $.014 moving nicely today
DMXC news...(see following)
Magnetometer Work Complete on the Delcer Buttes Gold/Copper Property
9:20a ET February 2, 2010 (Market Wire)
Delta Mining & Exploration Corporation (PINKSHEETS: DMXC) ("the Company") is pleased to announce that one part of the extensive geophysical work program has been completed on Delcer Buttes gold/copper property in Elko County.
Gradient Geophysics, Inc. ("Gradient") is working with Delta in conducting high-resolution magnetometer and high-powered induced polarization ("IP") surveys to identify potential copper/gold skarn mineralization and possible sediment hosted mineralization which may lie beneath extensive covered areas.
Thus far the magnetometer portion of the program has been completed and the data is currently being assembled and analyzed. Gradient will provide the Company a detailed interpretive map of the results which will be made available to the public. The IP surveys are yet to be completed due to the snowy conditions on the ground, but once those are finalized an advanced computer model will be used to assist the Company in evaluating the potential size of the mineralization at the property.
Also, last week the company filed paperwork with Pink OTC Markets Inc ("Pinksheets"), the parent company of Pinksheets.com, for status upgrade. After initial review, Pinksheets sent Delta comments which are currently being handled by corporate counsel. This is a common practice by Pinksheets and the Company is doing everything it can to comply with their requirements and expedite the process.
Delta will continue to issue updates regarding Pinksheets and the work program as new information becomes available
About Gradient Geophysics
Gradient has been on the forefront of geophysical data surveying and interpretation for mineral exploration for many years. Responsible for over 600 projects throughout the Americas, Gradient has worked extensively in the mining sector, conducting large-scale geophysical programs for major mining companies such as Rio Tinto, BHP, Newmont and Barrick and for many junior exploration companies. Gradient focuses on high-resolution magnetometer and high-powered IP data collection using robust computer modeling methods for advanced interpretation of mineral deposits.
About Delta Mining and Exploration Corp., http://www.deltamine.com: Delta Mining and Exploration Inc. is an emerging exploration company whose main objective is to locate and explore land with mineral and precious metal deposits in the mining rich regions of North America. Delta currently owns mineral rights to land in central Montana as well as the rights to 31 claims and 680 acres of land in Elko County Nevada.
NOTE: Safe Harbor for Forward-Looking Statements.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the Company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing, and other risks described in the Company's SEC reports and filings.
Contact:
Delta Mining and Exploration
917-331-0076
Email Contact
www.deltamine.com
SOURCE: Delta Mining and Exploration
http://www2.marketwire.com/mw/emailprcntct?id=EC0E53B038537AB4
http://www.deltamine.com
DMXC $.0121 x $.0129 looking ready for upward movement today
sheesh...you sound like a bitter bagholder...did you buy over $3 or something? lol
you can't discount the licensing agreement.
because when it was trading at less than a dollar they probably weren't well capitalized...had fewer drugs in R&D...no licensing agreements...etc. etc.
Were you on the conference call yesterday?
Achillion Pharmaceuticals Raised To Outperform From Neutral By Wedbush Morgan >ACHNLast update: 2/2/2010 8:45:10 AM(END) Dow Jones NewswiresFebruary 02, 2010 08:45 ET (13:45 GMT)
ACHN looking very strong pre-market. Strong news out at the closing bell yesterday followed by a strong conference call should result in a strong trading day here for ACHN.
DMXC $.012 x $.0135 gapping pre-market...perhaps today is the day?
need some news here IMO
looking for a strong week here
BGOI nice close there bud